TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2734721

Group type: EXPERIMENTAL
Intervention: Ornidazole administered by one daily IV infusion at 20 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ornidazole administered by two daily IV infusions at 20 mg/kg
Number of subjects: 12
Study: 31948990

Group type: EXPERIMENTAL
Intervention: TKR plus 12 weeks of supervised non-surgical treatment (exercise, education, diet, insoles and pain medication)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-surgical treatment alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TKR plus non-surgical treatment
Number of subjects: 100
Study: 30900905

Group type: EXPERIMENTAL
Intervention: Buccal dissolution test with polymer coatings (Surelease:Opadry at 8, 12, and 16% weight gain; Opadry EC at 4, 6, and 8% weight gain; Kollicoat Smartseal 100P at 10% weight gain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: USP I (basket) dissolution test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kollicoat Smartseal 100P coating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surelease:Opadry coating
Number of subjects: 0
Study: 27636178

Group type: EXPERIMENTAL
Intervention: Motionless ultrasonic toothbrush
Number of subjects: 25

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 25010354

Group type: EXPERIMENTAL
Intervention: Alert Program for Self‐Regulation® (TXT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Delayed treatment control (DTC)
Number of subjects: 25
Study: 23785019

Group type: EXPERIMENTAL
Intervention: udenafil 100 mg
Number of subjects: 118
Study: 21083516

Group type: EXPERIMENTAL
Intervention: Enoxaparin T (40 mg daily for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enoxaparin R (40 mg daily for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both LMWHs (T and R)
Number of subjects: 20
Study: 19299636

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17971525

Group type: EXPERIMENTAL
Intervention: 13‐cis‐RA and alpha‐tocopherol
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 9‐cis‐RA
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 15534051

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 35
Study: 11205424

Group type: COMPARATOR
Intervention: Placebo injections (two injections separated by 15 min)
Number of subjects: 20
Study: 9272133

Group type: COMPARATOR
Intervention: CHOP (standard therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: m-BACOD (third-generation regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM (third-generation regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MACOP-B (third-generation regimen)
Number of subjects: 0
Study: 8511091

Group type: EXPERIMENTAL
Intervention: HDCV 2 injections (days 0 and 28)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: HDCV 3 injections (days 0, 7, and 28)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: PVRV 2 injections (days 0 and 28)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: PVRV 3 injections (days 0, 7, and 28)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Booster dose at 1 year
Number of subjects: 312
Study: 3493614

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg X kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thiopentone 5 mg X kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol and Thiopentone
Number of subjects: 120
Study: 28586524

Group type: COMPARATOR
Intervention: Experiential self-focus
Number of subjects: 80

Group type: COMPARATOR
Intervention: Analytic self-focus
Number of subjects: 80
Study: 27417045

Group type: EXPERIMENTAL
Intervention: Somatosensory evoked magnetic fields (SEFs) recorded following median nerve stimulation with single and double pulses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants (not specified)
Number of subjects: 0
Study: 26522104

Group type: EXPERIMENTAL
Intervention: Noninvasive prenatal test (NIPT) using Illumina HiSeq massively parallel sequencing platform
Number of subjects: 917
Study: 24199979

Group type: EXPERIMENTAL
Intervention: Integrated yoga
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard antenatal exercises (Control)
Number of subjects: 96
Study: 20526530

Group type: EXPERIMENTAL
Intervention: Levothyroxine plus 100 microg sodium‐selenite (group B)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Levothyroxine alone (group A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Levothyroxine plus 200 microg sodium‐selenite (group C)
Number of subjects: 49
Study: 18212711

Group type: EXPERIMENTAL
Intervention: Maximal strength-training group (heavy loads: 80% to 98% of 1-RM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maximal velocity-training group (light loads: 25% to 50% of 1-RM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 16377282

Group type: EXPERIMENTAL
Intervention: Morning intake of atorvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evening intake of atorvastatin
Number of subjects: 0
Study: 14645783

Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Active Informational Control (HIV-Info)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Waiting-List Control (WLC)
Number of subjects: 149
Study: 11314241

Group type: EXPERIMENTAL
Intervention: Mud bath treatment (group A)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Bath treatment alone (group B)
Number of subjects: 37
Study: 9086543

Group type: EXPERIMENTAL
Intervention: Closed suction drainage
Number of subjects: 186

Group type: COMPARATOR
Intervention: Open drainage
Number of subjects: 186

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 186
Study: 8168879

Group type: EXPERIMENTAL
Intervention: Reamed nailing (RN; n = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unreamed nailing (UN; n = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: External fixation (EF; n = 8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transpulmonary TXB2-clearance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TXB2 and PGF2 alpha
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Early fracture stabilisation
Number of subjects: 30
Study: 3295573

Group type: EXPERIMENTAL
Intervention: Amizepin POLFA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tegretol GEIGY
Number of subjects: 10
Study: 30971133

Group type: EXPERIMENTAL
Intervention: Repair of the pronator quadratus (PQ) muscle after volar plating
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonrepair of the pronator quadratus (PQ) muscle after volar plating
Number of subjects: 0
Study: 31626990

Group type: EXPERIMENTAL
Intervention: Intravenous reslizumab 3.0 mg/kg every 4 weeks for 52 weeks
Number of subjects: 953

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 953
Study: 30509675

Group type: EXPERIMENTAL
Intervention: Cefiderocol (2 g) administered intravenously three times daily for 7-14 days
Number of subjects: 452

Group type: COMPARATOR
Intervention: Imipenem-cilastatin (1 g each) administered intravenously three times daily for 7-14 days
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Cefiderocol (2 g)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Imipenem-cilastatin (1 g each)
Number of subjects: 452
Study: 28076940

Group type: EXPERIMENTAL
Intervention: Iso sorbide mononitrate (ISMN) 60 mg sustained release, self-administered vaginally every other day for five doses
Number of subjects: 144

Group type: COMPARATOR
Intervention: Pyridoxine 10 mg (control)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Iso sorbide mononitrate (ISMN)
Number of subjects: 144
Study: 22257581

Group type: EXPERIMENTAL
Intervention: i.v. 1 mg tolvaptan
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: oral 30 mg tolvaptan
Number of subjects: 14

Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 14
Study: 20378094

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photodynamic therapy
Number of subjects: 0
Study: 18190618

Group type: EXPERIMENTAL
Intervention: Auxiliary covariates adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard analyses
Number of subjects: 0
Study: 16201207

Group type: EXPERIMENTAL
Intervention: Intervention activities during pregnancy
Number of subjects: 175

Group type: COMPARATOR
Intervention: Higher Fagerström test score
Number of subjects: 175
Study: 11208541

Group type: EXPERIMENTAL
Intervention: Duodenal lipid perfusion at 1.5 kcal/min
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline perfusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Granisetron (10 microg/kg iv)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbohydrate and protein perfusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Duodenal lipid perfusion at 3 kcal/min
Number of subjects: 9
Study: 10023473

Group type: EXPERIMENTAL
Intervention: New through-the-eyelid technique for axial length measurement using 'A' scan ultrasound
Number of subjects: 0
Study: 7852604

Group type: EXPERIMENTAL
Intervention: EMD with saccadic eye movements
Number of subjects: 6

Group type: COMPARATOR
Intervention: EMD without saccadic eye movements (control)
Number of subjects: 6
Study: 2903727

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8514071

Group type: EXPERIMENTAL
Intervention: Midazolam (mean dose in vasovagal group)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Midazolam (mean dose in control group)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Moderate to severe diverticulosis (vasovagal group)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Moderate to severe diverticulosis (control group)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Medical intervention required (vasovagal group)
Number of subjects: 223
Study: 392375

Group type: EXPERIMENTAL
Intervention: Group A: decontaminated by nonabsorbable antibiotics in strict reverse isolation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B: isolated only
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group C: treated under routine hospital conditions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group C
Number of subjects: 60
Study: 30645611

Group type: EXPERIMENTAL
Intervention: Curved-tip DLT (135 degree angle)
Number of subjects: 1427

Group type: COMPARATOR
Intervention: Control group (standard DLT without bent tip)
Number of subjects: 1427
Study: 28116314

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 43
Study: 26523663

Group type: EXPERIMENTAL
Intervention: Injury-Prevention Program (IPP)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Dynamic Warm-Up (DWU)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Static Warm-Up (SWU)
Number of subjects: 89
Study: 23635998

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 20
Study: 21461596

Group type: EXPERIMENTAL
Intervention: PGE(1) infusion (2.5 ng/kg/min) for 4 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (placebo) for 4 weeks
Number of subjects: 11
Study: 19717964

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study: 17198774

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg orally the day before and the morning of the operation, a bolus of 150 mg/kg of intravenous N-acetylcysteine before skin incision, followed by perfusion at 12.5 mg x kg(‐1) x h(‐1) over 24 hours; n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 14987884

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided treatment (n=124)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard care (n=119)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 243
Study: 11478788

Group type: EXPERIMENTAL
Intervention: N(omega)-carboxymethyl-arginine (CMA) in diabetic serum proteins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-matched control serum proteins
Number of subjects: 0
Study: 9764348

Group type: EXPERIMENTAL
Intervention: Heparin/Aspirin (H/A) alone
Number of subjects: 687

Group type: COMPARATOR
Intervention: Heparin/Aspirin (H/A) not administered
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Heparin/Aspirin (H/A) with Intravenous Immunoglobulin G (IVIg)
Number of subjects: 687
Study: 7924720

Group type: EXPERIMENTAL
Intervention: Traumatic incontinence
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Idiopathic incontinence
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with sphincter defect
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with idiopathic incontinence
Number of subjects: 23
Study: 3276257

Group type: EXPERIMENTAL
Intervention: 200 micrograms budesonide per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 800 micrograms budesonide per day
Number of subjects: 30
Study: 31611626

Group type: EXPERIMENTAL
Intervention: Traditional pediatric scheme (for fast responders with MRD < 0.1% on day 29)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Intensive block-based chemotherapy (for slow responders with MRD > 0.1% on day 29)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Intensive block-based chemotherapy
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Overall treatment (both arms)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Intensive block therapy
Number of subjects: 278
Study: 30852574

Group type: EXPERIMENTAL
Intervention: Molidustat
Number of subjects: 252

Group type: COMPARATOR
Intervention: Darbepoetin (Control)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Epoetin (Control)
Number of subjects: 252
Study: 28340289

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 53
Study: 26108190

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide 400 mg/day for 8 days
Number of subjects: 53
Study: 23539322

Group type: EXPERIMENTAL
Intervention: Asha‐Life (AL) intervention delivered by HIV‐trained village women (Asha)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 68
Study: 21699802

Group type: EXPERIMENTAL
Intervention: UDCA and Methotrexate (MTX)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: UDCA and Colchicine
Number of subjects: 29
Study: 18374614

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily for 28 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 16869482

Group type: EXPERIMENTAL
Intervention: KES parenting training with behaviour exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: KES parenting training without behaviour exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative treatment (discussion of problems)
Number of subjects: 0
Study: 12590404

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-250 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Clomipramine (100-250 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 86
Study: 11465584

Group type: EXPERIMENTAL
Intervention: Drug that may increase the probability of survival by 20%
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Other distributions (Gaussian, J shape, uniform)
Number of subjects: 350
Study: 9587116

Group type: EXPERIMENTAL
Intervention: CYFRA 21‐1
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: TPS
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: TPS and CYFRA 21‐1
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both TPS and CYFRA 21‐1 positive
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Combined use of TPS and CYFRA 21‐1
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 179
Study: 7821189

Group type: EXPERIMENTAL
Intervention: Normoalbuminuric IDDM patients with normal glomerular filtration rate
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: IDDM patients with hyperfiltration
Number of subjects: 39

Group type: COMPARATOR
Intervention: Age and sex matched controls
Number of subjects: 39
Study: 3054623

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 70
Study: 30753091

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Verbal behavior modification
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Acetaminophen and verbal behavior modification
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 28747245

Group type: EXPERIMENTAL
Intervention: General Practice Management Plan (GPMP)
Number of subjects: 6123

Group type: COMPARATOR
Intervention: Factors associated with receiving a GPMP
Number of subjects: 6123

Group type: COMPARATOR
Intervention: Mental Health Plan
Number of subjects: 6123
Study: 25872529

Group type: EXPERIMENTAL
Intervention: Decision coaching with up to three face-to-face coaching sessions with a trained nurse
Number of subjects: 300

Group type: COMPARATOR
Intervention: Counselling as usual (control group)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Decision coaching
Number of subjects: 300
Study: 24226720

Group type: EXPERIMENTAL
Intervention: Reformulated Ensure Plus
Number of subjects: 1771

Group type: COMPARATOR
Intervention: Other oral nutritional supplements
Number of subjects: 1771
Study: 21121958

Group type: EXPERIMENTAL
Intervention: PISFOP
Number of subjects: 54

Group type: COMPARATOR
Intervention: GCFOP
Number of subjects: 54
Study: 19267582

Group type: EXPERIMENTAL
Intervention: NovoFine 32‐gauge tip x 6 mm
Number of subjects: 119

Group type: COMPARATOR
Intervention: NovoFine 30‐gauge tip x 8 mm
Number of subjects: 119
Study: 18032219

Group type: EXPERIMENTAL
Intervention: 1,000 g/d of B12 for participants with MMA > 271 nmol/L
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0, 25, or 100 microg/d of B12 for participants with MMA <= 271 nmol/L
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 93
Study: 15617459

Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 330

Group type: COMPARATOR
Intervention: losartan 50 mg
Number of subjects: 330

Group type: COMPARATOR
Intervention: losartan 100 mg
Number of subjects: 330
Study: 11765098

Group type: EXPERIMENTAL
Intervention: Interventions to elicit emergency care by patients at times of distress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training in problem-solving strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive interventions including problem solving with intensive rehearsal of cognitive, social, emotional-labeling, and distress-tolerance skills
Number of subjects: 0
Study: 9460431

Group type: EXPERIMENTAL
Intervention: Biofeedback‐assisted pelvic floor muscle training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prompted voiding
Number of subjects: 0
Study: 8223837

Group type: EXPERIMENTAL
Intervention: Nizatidine (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine (450 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine pretreatment
Number of subjects: 0
Study: 3512633

Group type: EXPERIMENTAL
Intervention: Meclofenamate
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Meclofenamate (open trial)
Number of subjects: 103
Study: 30232857

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion plus diet control
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diet control
Number of subjects: 60
Study: 26229089

Group type: EXPERIMENTAL
Intervention: atrasentan 0.75 mg/day
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: atrasentan 1.25 mg/day
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: atrasentan (responders with >30% albuminuria reduction)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: atrasentan (non-responders)
Number of subjects: 211

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 211
Study: 25241957

Group type: EXPERIMENTAL
Intervention: Kinesthetic method
Number of subjects: 74

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 74
Study: 22531973

Group type: EXPERIMENTAL
Intervention: 4-5 e-mail reminders
Number of subjects: 3876

Group type: EXPERIMENTAL
Intervention: 11 e-mail reminders
Number of subjects: 3876

Group type: COMPARATOR
Intervention: Medium amounts of reminders (reference)
Number of subjects: 3876

Group type: EXPERIMENTAL
Intervention: High amounts of reminders
Number of subjects: 3876

Group type: EXPERIMENTAL
Intervention: Office workers
Number of subjects: 3876

Group type: EXPERIMENTAL
Intervention: Field workers
Number of subjects: 3876

Group type: EXPERIMENTAL
Intervention: Frequent reminders
Number of subjects: 3876

Group type: EXPERIMENTAL
Intervention: September
Number of subjects: 3876
Study: 19508966

Group type: EXPERIMENTAL
Intervention: CRx-102 (prednisolone 3 mg/day and dipyridamole 400 mg/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Composite scores
Number of subjects: 83
Study: 17459064

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intervention tool (structured pamphlet)
Number of subjects: 91